{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:04:55Z","timestamp":1794661495463,"version":"4.9.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.semarthrit.2024.152546","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T21:09:48Z","timestamp":1725743388000},"page":"152546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Barriers and facilitators to application of treat-to-target management in psoriatic arthritis and axial spondyloarthritis in practice: A systematic literature review"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-8547","authenticated-orcid":false,"given":"Casper","family":"Webers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette","family":"Essers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin","family":"Been","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"van Tubergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2024.152546_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0003","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102398","article-title":"Treat to target in axial spondyloarthritis: from its concept to its implementation","volume":"110","author":"Dougados","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0005","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/annrheumdis-2013-203860","article-title":"Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis","volume":"73","author":"Schoels","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0006","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","article-title":"Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update","volume":"75","author":"Stoffer","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0007","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0008","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0009","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0010","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","article-title":"Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial","volume":"80","author":"Molto","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0011","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kead634","article-title":"Factors associated with treatment intensification in patients with axial spondyloarthritis and high disease activity in clinical practice","author":"Webers","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0012","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/rheumatology\/keab516","article-title":"Treat-to-target in axial spondyloarthritis: an observational study in daily practice","volume":"61","author":"Beckers","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0013","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/rheumatology\/kead155","article-title":"Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target","volume":"63","author":"Bolt","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0014","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/art.40391","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis\/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000221","article-title":"When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS)","volume":"2","author":"Gvozdenovic","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13012-017-0605-9","article-title":"A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems","volume":"12","author":"Atkins","year":"2017","journal-title":"Implement Sci"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0017","doi-asserted-by":"crossref","first-page":"123","DOI":"10.15171\/ijhpm.2015.54","article-title":"Translating evidence into healthcare policy and practice: single versus multi-faceted implementation strategies - is there a simple answer to a complex question?","volume":"4","author":"Harvey","year":"2015","journal-title":"Int J Health Policy Manag"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0018","unstructured":"van Tubergen A., Boonen A., Essers I., et al. Barriers and facilitators to application of treat-to-target management in rheumatology practice: a systematic literature review. PROSPERO [serial on the Internet]. 2021; CRD42021247999: Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=247999."},{"key":"10.1016\/j.semarthrit.2024.152546_bib0019","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/annrheumdis-2020-217301","article-title":"Mixed methods study of clinicians' perspectives on barriers to implementation of treat to target in psoriatic arthritis","volume":"79","author":"Dures","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.31138\/mjr.31.1.145","article-title":"Treating to target in clinical practice: the results of a questionnaire completed by greek rheumatologists","volume":"31","author":"Karatsourakis","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0021","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/acr.23460","article-title":"Value of the routine assessment of patient index Data 3 in patients with psoriatic arthritis: results from a tight-control clinical trial and an observational cohort","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0022","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13075-018-1659-z","article-title":"Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway","volume":"20","author":"Haugeberg","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0023","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/rheumatology\/keaa766","article-title":"Measuring disease activity in psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden","volume":"60","author":"Mulder","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0024","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/annrheumdis-2018-214140","article-title":"Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries","volume":"78","author":"Gorlier","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3899\/jrheum.180267","article-title":"What should be the primary target of \"Treat to Target\" in psoriatic arthritis?","volume":"46","author":"Coates","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0026","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/annrheumdis-2017-211998","article-title":"Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort","volume":"77","author":"van Mens","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10235659","article-title":"Implementation of the treat-to-target concept in evaluation of psoriatic arthritis patients","volume":"10","author":"Gazitt","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0028","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10067-018-4383-9","article-title":"Treating psoriatic arthritis to target: discordance between physicians and patients' assessment, non-adherence, and restricted access to drugs precluded therapy escalation in a real-world cohort","volume":"38","author":"Ferreira","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0029","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13075-017-1424-8","article-title":"Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice","volume":"19","author":"van Mens","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0030","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/rheumatology\/kex183","article-title":"Residual disease activity in psoriatic arthritis: discordance between the rheumatologist\u2019s opinion and minimal disease activity measurement","volume":"57","author":"van Mens","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0031","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3899\/jrheum.151101","article-title":"Patients with psoriatic arthritis fulfilling the minimal disease activity criteria do not have swollen and tender joints, but have active skin","volume":"43","author":"Marin","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016619","article-title":"Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry","volume":"7","author":"Rahman","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0033","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1093\/rheumatology\/keab711","article-title":"Exploring remission concept in axial spondyloarthritis through the perception of rheumatologists using vignettes and priority ratings","volume":"61","author":"Aouad","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0034","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-023-03055-1","article-title":"Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?","volume":"25","author":"Maksymowych","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0035","first-page":"808","article-title":"What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?","volume":"37","author":"Bakirci","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0036","first-page":"512","article-title":"Analysis of potential determinants for a treat-to-target strategy in psoriatic arthritis patients from a real-world setting","volume":"37","author":"Lubrano","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152237","article-title":"Treat-to-target in real-life psoriatic arthritis patients: achieving minimal disease activity with bDMARDs\/tsDMARDs and potential barriers","volume":"62","author":"Ortolan","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0038","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1080\/14397595.2017.1367076","article-title":"Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors","volume":"28","author":"Monti","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0039","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/03009742.2023.2213509","article-title":"Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study","volume":"53","author":"Michielsens","year":"2024","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0040","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/annrheumdis-2016-210283","volume":"76","author":"Michelsen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0041","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1136\/annrheumdis-2021-eular.3438","article-title":"AB0564 rheumatologists\u2019 views and experiences in managing psa patients based on treating to target strategy: a cross-sectional study in China","volume":"80","author":"Xu","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0042","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/acr.23293","article-title":"Cost-effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of a multicenter randomized controlled trial","volume":"70","author":"O\u2019Dwyer","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0043","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rdc.2018.09.007","article-title":"Challenges in implementing treat-to-target strategies in rheumatology","volume":"45","author":"Ford","year":"2019","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0044","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/annrheumdis-2022-eular.2830","article-title":"POS0607 improving treat-to-target implementation in rheumatoid arthritis: a systematic literature review of barriers, facilitators, and interventions","volume":"81","author":"Gossec","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3899\/jrheum.170449","article-title":"Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature","volume":"45","author":"Gossec","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0046","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.berh.2018.08.004","article-title":"Disease activity assessment in patients with psoriatic arthritis","volume":"32","author":"Kerschbaumer","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0047","doi-asserted-by":"crossref","first-page":"vi18","DOI":"10.1093\/rheumatology\/key176","article-title":"Defining the target: clinical aims in axial spondyloarthritis","volume":"57","author":"Marzo-Ortega","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0048","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152546_bib0049","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.282.15.1458","article-title":"Why don't physicians follow clinical practice guidelines? A framework for improvement","volume":"282","author":"Cabana","year":"1999","journal-title":"JAMA"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T20:52:51Z","timestamp":1732654371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224001860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":49,"alternative-id":["S0049017224001860"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152546","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers and facilitators to application of treat-to-target management in psoriatic arthritis and axial spondyloarthritis in practice: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152546"}}